epi-7386 epi-7386 epi-7386 is an n-terminal domain antiandrogen, or antagonist of the n-terminal domain (ntd) of the androgen receptor (ar), which is under development for the treatment of prostate cancer. the compound was developed as a successor of previous drugs in the epi series such as epi-001, ralaniten (epi-002), and ralaniten acetate (epi-506). epi-7386 shows 20-fold higher antiandrogenic potency than ralaniten in vitro (ic50 = 535 nm vs. 9,580 nm, respectively), as well as greater stability in human hepatocytes. it is planned to enter phase i clinical trials in 2020. epi-7386clinical dataroutes ofadministrationby mouthdrug classn-terminal domain antiandrogen